Study of 131I-8H9, a radiolabeled antibody for the treatment of relapsed neuroblastoma

Trial Profile

Study of 131I-8H9, a radiolabeled antibody for the treatment of relapsed neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Burtomab I 131 (Primary)
  • Indications Neuroblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Y-mAbs Therapeutics
  • Most Recent Events

    • 07 Jun 2017 According to a Memorial Sloan-Kettering Cancer Center media release, based on the data from this study, the FDA has granted the Breakthrough Therapy Designation to burtomab for the treatment of pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis.
    • 04 Jun 2017 Results (n=80) from this trial published in a Y-mAbs Therapeutics Media Release.
    • 28 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top